The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...

Syndax Pharmaceuticals (SNDX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kelly ...

The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating relapsed or ...

Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Syndax Pharmaceuticals (SNDX – Research Report). The associated ...

Syndax Pharmaceuticals (NASDAQ:SNDX) just reported positive results from the phase 2 portion of its AUGMENT-101m trial evaluating the use of Revumenib for the treatment of patients with relapsed ...

Syndax (SNDX) announced that multiple abstracts evaluating revumenib, an oral small molecule menin inhibitor, have been accepted for oral presentation at the 66th American Society of Hematology ...

"The data being presented this year at ASH demonstrate Syndax's commitment to develop revumenib as a practice-changing therapy for adult and pediatric patients with acute leukemias," said Neil ...

Also Read: FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication Among the patients who achieved CR/CRh, 12 had a CR, and three had a CRh.

Syndax Pharmaceuticals , Inc. (NASDAQ:SNDX) is a biotechnology company focused on developing innovative cancer therapies. With recent FDA approvals and upcoming regulatory decisions, Syndax is ...